ReviewCurrent allergy and asthma reports2014
Interleukin-31: a novel diagnostic marker of allergic diseases.
Review in Current allergy and asthma reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.JAMA dermatology · 2020Trial
- Cross-regulation between the nervous system and type 2 immunity.Science immunology · 2025Review
- Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.American journal of clinical dermatology · 2025Review
- Does IL-31 level have more significance in chronic urticaria, when compared with IL-33 level?Postepy dermatologii i alergologii · 2025Article
- Anti-Pruritic and Immunomodulatory Effects of Coix [International journal of molecular sciences · 2024Article
- Anti-atopic dermatitis effect of fraxinellone via inhibiting IL-31 in vivo and in vitro.Heliyon · 2024Article
- PDE4D and miR-203 are promising biomarkers for canine atopic dermatitis.Molecular biology reports · 2024Article
- Mast cell-sensory neuron crosstalk in allergic diseases.The Journal of allergy and clinical immunology · 2024Review
- Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human.Frontiers in medicine · 2024Review
- Interleukin (IL)-23, IL-31, and IL-33 Play a Role in the Course of Autoimmune Endocrine Diseases.Endocrine, metabolic & immune disorders drug targets · 2024Article
- The IL-33/IL-31 Axis in Allergic and Immune-Mediated Diseases.International journal of molecular sciences · 2023Article
- Serum sCD40L and IL-31 in Association with Early Phase of IgA Nephropathy.Journal of clinical medicine · 2023Article
- Protease-activated receptors in health and disease.Physiological reviews · 2023Review
- The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.Life (Basel, Switzerland) · 2022Review
- Tuning SLOCK toward Chronic Disease Diagnostics and Management: Label-free Sweat Interleukin-31 Detection.ACS omega · 2021Article
- Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.International journal of molecular sciences · 2021Review
- Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA.Biochemistry · 2020Article
- Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.Acta dermato-venereologica · 2020Article
- Interleukin-31 Receptor α Is Required for Basal-Like Breast Cancer Progression.Frontiers in oncology · 2020Article
- Inhibition of natriuretic peptide receptor 1 reduces itch in mice.Science translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-31 (IL-31) is a newly discovered cytokine associated with chronic skin inflammation and pruritus. Patients with atopic dermatitis, chronic spontaneous urticaria, allergic contact dermatitis, prurigo nodularis, primary cutaneous lymphoma and mastocytosis exhibit increased serum levels of IL-31 protein and elevated IL-31 mRNA in the skin. Interestingly, in some of these diseases, IL-31 serum levels correlate with disease activity. In the present review, we particularly focus on studies investigating IL-31 as a novel diagnostic biomarker indicating the severity of allergic diseases. We highlight a recent study on IL-31 in mastocytosis, which reports on elevated serum levels of IL-31 in adults correlating with the severity of disease categories, tryptase levels and percentage of bone marrow infiltration. We conclude that growing knowledge about IL-31, its receptors and signaling pathways serves to better understand the pathogenesis of allergic diseases and may lead to the development of novel treatment approaches.
Indexed as
Identifiers
24510535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.